Chardan Capital Markets reiterated a Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $16.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback November 29, 2016 7:59 AM Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird November 29, 2016 7:00 AM After-Hours Stock Movers 09/01: (THO) (TIVO) (VNET) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)November 28, 2016 5:57 PM Amicus Therapeutics (FOLD) Reports Regulatory Pathway in U.S. for Migalastat for Fabry DiseaseNovember 28, 2016 4:11 PM Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry DiseaseNovember 28, 2016 4:09 PM